NCT07031323 OnTrackCF: Engagement, Feasibility, and Acceptability Study
| NCT ID | NCT07031323 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Children's Hospital |
| Condition | Cystic Fibrosis (CF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-11-20 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-11-20 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with CF 2. 18+ years of age 3. Prescribed a CFTR modulator therapy to be taken twice a day 4. Can speak and read English 5. Have regular access to an iOS or Android tablet or smartphone with internet access. Exclusion Criteria: 1\) Any situation, in the opinion of the Investigator, that would compromise the safety of the patient or the quality of the data
Contact & Investigator
Kristin Riekert, PhD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT07031323 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cystic Fibrosis (CF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07031323 currently recruiting?
Yes, NCT07031323 is actively recruiting participants. Contact the research team at emma.mcwilliams@childrens.harvard.edu for enrollment information.
Where is the NCT07031323 trial being conducted?
This trial is being conducted at Birmingham, United States, Baltimore, United States, Boston, United States.
Who is sponsoring the NCT07031323 clinical trial?
NCT07031323 is sponsored by Boston Children's Hospital. The principal investigator is Kristin Riekert, PhD at Johns Hopkins University. The trial plans to enroll 60 participants.